These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12460701)

  • 1. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
    Franscini LM; Von Vigier RO; Pfister R; Casaulta-Aebischer C; Fossali E; Bianchetti MG
    Am J Hypertens; 2002 Dec; 15(12):1057-63. PubMed ID: 12460701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
    Gartenmann AC; Fossali E; von Vigier RO; Simonetti GD; Schmidtko J; Edefonti A; Bianchetti MG
    Kidney Int; 2003 Oct; 64(4):1450-4. PubMed ID: 12969165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
    Simonetti GD; von Vigier RO; Konrad M; Rizzi M; Fossali E; Bianchetti MG
    Pediatr Nephrol; 2006 Oct; 21(10):1480-2. PubMed ID: 16802178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
    J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
    Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
    Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
    Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
    Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
    Pouleur HG
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus].
    Zukowska-Szczechowska E; Gosek K; Grzeszczak W
    Przegl Lek; 2002; 59(3):160-4. PubMed ID: 12184030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of anti-hypertensive therapy with irbesartan on the absolute cardiovascular risk].
    Coca A; Ruilope LM; Calvo C; de la Sierra A; Aranda P; Luque M; Marín-Iranzo R;
    Rev Clin Esp; 2003 Apr; 203(4):183-8. PubMed ID: 12681201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.
    Debernardi-Venon W; Barletti C; Alessandria C; Marzano A; Baronio M; Todros L; Saracco G; Repici A; Rizzetto M
    Dig Dis Sci; 2002 Feb; 47(2):401-4. PubMed ID: 11855558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
    J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 20. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.